CD8A and neoplasm: The combined use of IR and anti-PD-L1 stimulates CD8+ T-cell responses and reduces the local concentration of MDSCs within the tumour via tumour necrosis factor (TNF), thereby enhancing the immune microenvironment of the tumour and consequently producing anti-tumour effects [33].